Related Experiment Video
Updated: Apr 26, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
IFNα induces prolonged remissions modeling curative immunologic responses in chronic myeloid leukemia
Mette Ilander1, Anna Kreutzman1, Satu Mustjoki1
1Hematology Research Unit; Department of Hematology; University of Helsinki and Helsinki University Central Hospital Cancer Center; Helsinki, Finland.
Abstract:
Tyrosine kinase inhibitor therapy has dramatically changed the outcome of chronic myeloid leukemia (CML) patients. However, the treatment is not considered to be curative and may present deleterious side effects, such that additional therapy options are warranted. Here, we discuss the beneficial immunomodulatory effects of interferon α (IFNα) therapy and the immunological changes related to optimal treatment responses.

